Injectable Testosterone Shortage: Supply Anticipated Soon
CSEM is aware of ongoing and regular shortages of injectable testosterone (Delatestryl and Depo-Testosterone). Through multi-stakeholder meetings with Health Canada, we have learned that:
- Bausch Health (Delatestryl - testosterone enanthate) has experienced a shortage for several months due to material supply issues as a result of the pandemic. Bausch anticipates releasing supply this week with 2nd and 3rd supply lots arriving by mid-October and a return to normal supply in December. Initially, supply will be limited and allocated across the country as a percentage of sales.
- Pfizer Canada (Depo-Testosterone - testosterone cypionate) is also experiencing a shortage due to increased demand as result of the Bausch shortage. Pfizer anticipates testosterone will be back in stock by the end of October with enough supply to fill usual demand. Availability may vary depending on the Bausch supply.
- Health Canada is monitoring the ongoing shortages and will provide us with bi-weekly updates.
CSEM has requested that Health Canada:
- not only monitor the ongoing shortages but help support industry initiatives to reduce shortages;
- advocate for all provinces to allow patients to use transdermal testosterone if injectable is not available.
We will update our website with new information as it becomes available.